INCMGA00012 (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Phase I/II Study of Gemcitabine and Docetaxel Combined With Immune Checkpoint Blockade (INCMGA00012) in Patients With Advanced Soft Tissue Sarcoma

This study is being done to find out whether the study drug INCMGA00012, a monoclonal antibody against the PD-1 protein, combined with gemcitabine and docetaxel, is a safe and effective treatment for your disease. Gemcitabine and docetaxel are chemotherapy drugs that are commonly used to treat soft tissue sarcoma. INCMGA00012 is an experimental drug that boosts the immune system's ability to fight cancer cells. The study researchers think that INCMGA00012 may help gemcitabine and docetaxel work better against soft tissue sarcoma that is either locally advanced or has spread beyond its original location (metastasized), and it cannot be removed with surgery (unresectable).

INCMGA00012 (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Recruitment

Summary

Participation Requirements

Description

Tracking Information